1. Home
  2. Analysis
  3. Seroquel
  4. Zarxio

Seroquel and Zarxio drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Seroquel (quetiapine fumarate) and Zarxio (filgrastim-sndz). Common drug interactions include headache among females.

The phase IV clinical study analyzes what interactions people have when they take Seroquel and Zarxio. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Seroquel?

Seroquel has active ingredients of quetiapine fumarate. It is often used in bipolar disorder. eHealthMe is studying from 120,285 Seroquel users. Check the latest studies of Seroquel.

What is Zarxio?

Zarxio has active ingredients of filgrastim-sndz. eHealthMe is studying from 3,250 Zarxio users. Check the latest studies of Zarxio.

On Jul, 13, 2026

18 people who take Seroquel and Zarxio together, and have interactions are studied.

Seroquel and Zarxio drug interactions.

What are the common drug interactions of Seroquel and Zarxio, by gender? *:

female:

  1. Headache (pain in head)
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Decreased appetite
  4. Fall
  5. Fatigue (feeling of tiredness)
  6. Fluid retention (an abnormal accumulation of fluid in the blood)
  7. Gastrointestinal pain
  8. Influenza like illness
  9. Kidney infection
  10. Localised infection (infection at the single location)

male:

n/a

What are the common drug interactions of Seroquel and Zarxio, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Death

60+:

  1. Limb injury
  2. Macular degeneration (painless eye condition that leads to the gradual loss of central vision)
  3. Pneumonia
  4. Urinary tract infection
  5. White blood cell count increased

What are the existing conditions these people have? *

  1. Immunodeficiency Common Variable: 10 people, 55.56%
  2. Multiple Myeloma (cancer of the plasma cells): 4 people, 22.22%
  3. White Blood Cell Disorder: 3 people, 16.67%
  4. Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 1 person, 5.56%
  5. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Seroquel and Zarxio?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Seroquel and Zarxio:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Seroquel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Zarxio:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Seroquel and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zarxio and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on quetiapine fumarate and filgrastim-sndz (the active ingredients of Seroquel and Zarxio, respectively), and Seroquel and Zarxio (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.